Literature DB >> 18562238

Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.

Radu Constantinescu1, Henrik Zetterberg, Björn Holmberg, Lars Rosengren.   

Abstract

Parkinsonian disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), are a large group of common neurodegenerative diseases. The initial differential diagnosis can be extremely challenging with major implications for prognosis. The 42 amino acid fragment of amyloid-beta (Abeta42), neurofilament light chain (NFL), neurofilament heavy chain (pNFH), tau protein, glial fibrillary acidic protein (GFAP), neuron specific enolase (NSE), S-100B protein, and myelin basic protein (MBP) are brain related proteins (BRP) present in neurons and glia cells. They are released in the cerebrospinal fluid (CSF) after brain tissue damage caused by a variety of neurological diseases, including the parkinsonian disorders. A review of the literature shows that, carefully interpreted, the CSF levels of BRP can be of value in the differential diagnosis of parkinsonian disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562238     DOI: 10.1016/j.parkreldis.2008.05.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  18 in total

1.  Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.

Authors:  Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow
Journal:  Exp Gerontol       Date:  2011-10-01       Impact factor: 4.032

2.  PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.

Authors:  Elizabeth K Lucas; Sarah E Dougherty; Laura J McMeekin; Courtney S Reid; Lynn E Dobrunz; Andrew B West; John J Hablitz; Rita M Cowell
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

3.  Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.

Authors:  Dana Wagshal; Sethu Sankaranarayanan; Valerie Guss; Tracey Hall; Flora Berisha; Iryna Lobach; Anna Karydas; Lisa Voltarelli; Carole Scherling; Hilary Heuer; Maria Carmela Tartaglia; Zachary Miller; Giovanni Coppola; Michael Ahlijanian; Holly Soares; Joel H Kramer; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Jere Meredith; Adam L Boxer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-04       Impact factor: 10.154

4.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

Review 5.  Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Authors:  Babak Jalilian; Halldór Bjarki Einarsson; Thomas Vorup-Jensen
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

6.  The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.

Authors:  Thomas E Angel; Jon M Jacobs; Serena S Spudich; Marina A Gritsenko; Dietmar Fuchs; Teri Liegler; Henrik Zetterberg; David G Camp; Richard W Price; Richard D Smith
Journal:  Clin Proteomics       Date:  2012-03-20       Impact factor: 3.988

7.  Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis.

Authors:  Simone A van den Berge; Josta T Kevenaar; Jacqueline A Sluijs; Elly M Hol
Journal:  Parkinsons Dis       Date:  2012-04-22

8.  Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS.

Authors:  Ching-Hua Lu; Axel Petzold; Bernadett Kalmar; James Dick; Andrea Malaspina; Linda Greensmith
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology.

Authors:  Chera L Maarouf; Thomas G Beach; Charles H Adler; Michael Malek-Ahmadi; Tyler A Kokjohn; Brittany N Dugger; Douglas G Walker; Holly A Shill; Sandra A Jacobson; Marwan N Sabbagh; Alex E Roher
Journal:  Biomark Insights       Date:  2013-03-12

10.  Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Authors:  Radu Constantinescu; Stefania Mondello
Journal:  Front Neurol       Date:  2013-01-21       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.